

JCO7 Rec'd PCT/PTO 06 FEB 2002

FORM PTO 1390 (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER HUBR-1204
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/049216</b>
INTERNATIONAL APPLICATION NO. <b>PCT/EP00/08279</b>	INTERNATIONAL FILING DATE <b>24 August 2000</b>	PRIORITY DATE CLAIMED <b>27 August 1999</b>	
TITLE OF INVENTION <b>MEDICAMENTS THAT CONTAIN XENOGENIC OLIGO- OR/AND POLYRIBONNUCLEOTIDES</b>			
APPLICANT(S) FOR DO/EO/US <b>Hugo SEINFELD</b>			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing 35 U.S.C. 371</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input checked="" type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input checked="" type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> </ol>			
<b>Items 11 to 20 below concern document(s) or information included:</b>			
<ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</li> <li>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>20. <input checked="" type="checkbox"/> Other items or information: <b>PCT/IPEA/416</b></li> </ol>			

25126127/1

06 FEB 2002

U.S. APPLICATION NO (if known, see 37 CFR 1.51) <div style="font-size: 1.5em; font-weight: bold;">107049216</div>	INTERNATIONAL APPLICATION NO <div style="font-weight: bold;">PCT/EP00/08279</div>	ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold;">HUBR-1204</div>																															
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> <div style="margin-left: 20px;"> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO . . . \$1040.00  <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . \$890.00  <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . \$740.00  <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . \$710.00  <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . \$100.00         </div> <div style="margin-left: 40px; font-weight: bold;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div> Surcharge of \$ <u>130.00</u> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		<b>CALCULATIONS</b> PTO USE ONLY      <table style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%; text-align: right;">\$ 890.00</td> <td style="width:50%;"></td> </tr> <tr> <td style="text-align: right;">\$ 130.00</td> <td></td> </tr> </table>	\$ 890.00		\$ 130.00																												
\$ 890.00																																	
\$ 130.00																																	
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;"></th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>20 2 -20 =</td> <td>1</td> <td>X</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>1-3 =</td> <td>0</td> <td>X</td> <td>\$</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(s) (if applicable)</td> <td>X \$ 1020.00</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td>\$ 1020.00</td> </tr> </tbody> </table> <div style="margin-left: 20px;"> <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.         </div> <div style="margin-left: 40px; font-weight: bold;">SUBTOTAL =</div> <div style="margin-left: 20px;">         Processing fee of \$ _____ for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +       </div> <div style="margin-left: 40px; font-weight: bold;">TOTAL NATIONAL FEE =</div> <div style="margin-left: 20px;">         Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment Must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) ( _____ per property). +       </div> <div style="margin-left: 40px; font-weight: bold;">TOTAL FEES ENCLOSED =</div>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total claims	20 2 -20 =	1	X	\$	Independent claims	1-3 =	0	X	\$	MULTIPLE DEPENDENT CLAIM(s) (if applicable)				X \$ 1020.00	<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1020.00	<table style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%; text-align: right;">\$ 1020.00</td> <td style="width:50%;"></td> </tr> <tr> <td style="text-align: right;">\$</td> <td></td> </tr> <tr> <td style="text-align: right;">\$</td> <td></td> </tr> </table>	\$ 1020.00		\$		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																														
Total claims	20 2 -20 =	1	X	\$																													
Independent claims	1-3 =	0	X	\$																													
MULTIPLE DEPENDENT CLAIM(s) (if applicable)				X \$ 1020.00																													
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1020.00																													
\$ 1020.00																																	
\$																																	
\$																																	
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1020.00</u> to cover the above fees is enclosed.  b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.  c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to my Deposit Account No. <u>50-0624</u> . A duplicate copy of this sheet is enclosed.		<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%; text-align: right;"><b>Amount to be Refunded:</b></td> <td style="width:50%; text-align: right;">\$</td> </tr> <tr> <td style="text-align: right;"><b>Charged:</b></td> <td style="text-align: right;">\$</td> </tr> </table>	<b>Amount to be Refunded:</b>	\$	<b>Charged:</b>	\$																											
<b>Amount to be Refunded:</b>	\$																																
<b>Charged:</b>	\$																																
<p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b></p> <div style="display: flex; justify-content: space-between;"> <div style="width:45%;">           SEND ALL CORRESPONDENCE TO:            James R. Crawford            FULBRIGHT &amp; JAWORSKI L.L.P.            666 Fifth Avenue            New York, New York 10103            (212) 318-3148            Customer No. 24972         </div> <div style="width:45%; text-align: center;"> <div style="font-size: 1.2em; font-weight: bold;">Signature</div> <div style="font-size: 1.2em; font-weight: bold;">NAME</div> <div style="margin-top: 20px; font-weight: bold;">39,155</div> </div> </div>																																	

666 FIFTH AVE

10/049216

JG13 Rec'd PCT/PTC 06 FEB 2002

Certificate of Express Mail

This mail is being sent by Express Mail No. EL 829643198 US  
In an envelope addressed to: Commissioner of Patents and Trademarks  
Washington, D.C. 20231 Box PCT  
On February 6, 2002

By: Eileen Sheffield

*Eileen Sheffield*

EL829643198US

WO 01/15704

PCT/EP00/08279

**Medicaments containing xenogeneic oligo- and/or  
 polyribonucleotides**

Description

5

The invention relates to medicaments which contain xenogeneic oligo- and/or polyribonucleotides as active ingredient. It furthermore relates to the use of said xenogeneic oligo- and/or polyribonucleotides for the treatment of Herpesviridae infections and skin malignancies.

10

Background of the invention

15

Viruses of the Herpesviridae family are pathogens which are common throughout the world and to which most vertebrates are susceptible. The most important human herpes viruses are herpes simplex virus 1 and 2 (HSV-1, HSV-2), varicella zoster virus (VZV) and human cytomegalovirus (HCMV). HSV causes, in immunocompetent individuals, lesions of the skin or mucosas, which can reappear as recurrences time and again with varying frequency. Various herpes viruses are distinguished according to the location of lesions, for example herpes labialis or herpes genitalis, etc.

20

25

Present methods of treatment for such viruses mainly aim at inhibition of viral replication, for example with Acyclovir, as [sic] known inhibitor of viral DNA polymerase. However, the virus can become resistant to Acyclovir with time and this is the case in particular for herpes simplex. In addition, although conventional agents can provide relief in the case of acute lesions, they cannot prevent recurrences effectively.

30

35

In the late 1960s and early 1970s, it was found in the context of transplant research, that tissue pretreated with xenogeneic heterogeneous nucleic acids or weak

2001-09-26 10:00

antigens had substantially increased antititers in various immunological examination methods. These results were confirmed further using a number of various antigens in *in vitro* and *in vivo* studies.

5 However, there was no indication that nucleic acids and in particular oligo- and/or polyribonucleotides of xenogeneic origin could be suitable for controlling viral infections.

10 At the same time, especially in the USA, experiments with defined synthetic poly- and oligonucleotides, particularly ribonucleotides, were carried out, which, however, were not pursued any further, due to the high toxicity *in vivo*.

15 It was therefore the object of the present invention to provide a medicament which is suitable for the treatment of Herpesviridae infections and also of malignant skin disorders. It was furthermore an object  
20 of the invention to provide a medicament which reduces the recurrence rate for lesions of the skin, in particular for lesions caused by viruses.

According to the invention, the object is achieved by a  
25 medicament which comprises xenogeneic oligo- and/or polyribonucleotides as active substance.

Xenogeneic in accordance with the present invention means that the ribonucleic acid originates from an  
30 organism different from the one to be treated therewith, i.e. those oligo- and/or polyribonucleotides which are not from the same organism as that to which the medicament is to be administered. The xenogeneic oligo- and/or polyribonucleotides used according to the  
35 invention are preferably those from animal tissue (e.g. bovine tissue, fetal calf tissue), plants and unicellular organisms, preferably from yeast cells (in particular *Saccharomyces cerevisiae*). Preference is given to using oligo- and/or polyribonucleotides of

organisms which are evolutionarily as distant as possible from the organism to be treated. Thus, in medicaments for humans preferably RNA from animal tissues or particularly preferably from plants or unicellular organisms such as, for example, yeast is used.

The invention is based on studies with RNA preparations in herpes infections. In this connection, it was found that applying isolated xenogeneic RNA to skin lesions of patients with herpes simplex labialis, herpes simplex cruris disseminata and herpes simplex genitalis, apart from the immediate action on the lesions themselves, in addition surprisingly also reduced significantly the recurrence rate in patients which had suffered over the year from frequently reappearing recurrences. It was then found that said RNA is active in a similar way also in the case of skin tumors, for example basaliomas.

The oligo- and/or polyribonucleotides used according to the invention are nontoxic and on their own nonantigenic.

It is possible to effectively use preparations of total RNA and salts and compounds thereof. Particular preference is given to tRNA. A particularly preferred manner of obtaining RNAs which can be used according to the invention is phenol extraction, specifically the methods denoted methods I and II herein.

The active amount of xenogeneic oligo- and/or polyribonucleotides per dosage depends in each patient on various factors, for example location of the lesions or size and extent of the affected area, and also type of administration. The dosage range is from 0.1 mg upward per dose unit. The lower limit of the amount per dose unit is preferably at least 0.5 mg, more preferably at least 2 mg, even more preferably at least

5 mg; and the upper limit is preferably 5 mg, more preferably 20 mg, even more preferably 10 mg.

The medicament of the invention preferably contains the xenogeneic oligo- and/or polyribonucleotides in essentially anhydrous form, for example as flakes, powder, granules, ointment or the like. However, the oligo- and/or polyribonucleotides may also be present in a soluble form in water or another solvent.

Additionally the medicament of the invention may comprise physiologically acceptable carriers, excipients, diluents and/or additives and/or adjuvants.

The pharmaceutical compositions which contain the xenogeneic oligo- and/or polyribonucleotides of the invention may be formulated for oral application as tablets, pastilles and chewable tablets, liquid suspensions, in powder form or as granules, emulsions, in hard or soft capsules, in syrup or elixir, as slow-release form or as osmotic capsules for slow release.

Another pharmaceutical form with particularly advantageous action is anhydrous ointments made of PEG mixtures.

Administration is carried out preferably topically, but also orally, parenterally, rectally or by inhalation. The term parenterally here relates to subcutaneous, intravenous, intramuscular and intrasternal injections or infusion techniques.

For topical application, the total RNA or tRNA used is preferably applied to the affected site as powder or PEG ointment (i.e. in anhydrous form); in the case of powder, the skin may be wetted slightly, where appropriate, and is preferably left to dry exposed to the air.

A particular embodiment of the invention is a medicament formulation for the treatment of disorders caused by Herpesviridae, which also reduces the frequency of recurrences in these disorders. The agent of the invention is particularly preferred for the treatment of lesions caused by herpes simplex viruses and herpes zoster (VZV), for example lesions and recurrences which are caused by herpes simplex labialis (herpes of the lips) and genitalis.

Xenogeneic oligo- and/or polyribonucleotides and the medicament of the invention are likewise suitable for treating skin malignancies such as, for example basaliomas.

The invention further relates to the use of said xenogeneic oligo- and/or polyribonucleotides for producing a medicament for the treatment of Herpesviridae disorders and skin tumors.

In the case of a lesion or a recurrence, a treatment is in each case preferably carried out as early as possible, and a single application already reduces the reappearance frequency.

In addition to treating humans with the xenogeneic oligo- and/or polyribonucleotides of the present invention, it is also possible to treat warm blooded animals such as, for example, horses, cattle, sheep, etc. in this way.

The following examples and experimental results further illustrate the invention.

## Examples

### Example 1

Production of the oligo- and/or polyribonucleotides usable according to the invention



The relevant literature describes a large number of methods for obtaining nucleic acids, nucleotides and nucleosides, which are known to anyone having the relevant experience. Two methods with small modifications, which are both based on phenolization, are preferably applied here, method I for obtaining the total RNA (Georgiev, G.P. and Mantieva, V. L., Biochim, Biophys. acta 61, 153 (1962)) and method II for obtaining the tRNA (Bauer, S. et al., Biotechnology and Bioengineering 15, 1081 (1973)). Both methods are suitable for extracting relatively large amounts.

#### Method I

A 15% suspension of brewer's yeast (*Saccharomyces cerevisiae*) was in buffer (A) [0.001 M EDTA, 0.01 M Tris-HCl buffer, pH 5-6, 25% sucrose, 0.5% SDS (sodium dodecyl sulfate), 0.3% Na deoxychlorate] was homogenized in a Waring Blendor [sic] at 10°C and 3000 rpm for 3 minutes. The homogenate was admixed with the same volume of solution (B) [80% recrystallized phenol in buffer (A), 0.1% 8-hydroxyquinoline, 1.2% diethylpyrocarbonate] and then slowly stirred at 60°C for 30 minutes. All buffer solutions were prepared with deionized water which had been agitated with bentonite beforehand.

The phenolized homogenate was then centrifuged at room temperature, approx. 20°C, and 10 000 g for 15 minutes. The aqueous phase was removed and the phenol and the intermediate phase were discarded. The aqueous phase was admixed with the same volume of a 1:1 mixture of solution (B) and chloroform/isoamyl alcohol (96:4) and extracted as described above. The aqueous phase was extracted three times with half the volume of diethyl ether in order to remove the remaining phenol. The solution was adjusted to 2% sodium acetate and the RNA was precipitated with 2.5 volumes of absolute ethanol.

The precipitated RNA was removed by centrifugation at 0°C and 5 000 rpm and taken up in an ice-cold 0.01 M Tris-HCl buffer, pH 7.0 and 0.001 M MgCl<sub>2</sub>. Possible DNA was degraded by adding electrophoretically pure pancreatic DNase (4 g/ml) to the solution and incubating at 22°C for 3 hours. Protein residues, the DNase and RNases were digested with pronase (10 µg/ml) at 37°C for 3 hours. During this time, pronase was also destroyed by digesting itself. The RNA solution was extracted as described above with solution (B) at 60°C with gentle stirring for 20 minutes, the phases were separated by centrifugation, the aqueous phase was removed and extracted with diethyl ether. After addition of sodium acetate (final concentration 2%), the RNA was precipitated with 2.5 volumes of ethanol and removed by centrifugation. The precipitate was taken up in cold 2% strength sodium acetate, precipitated with 2.5 volumes of ethyl alcohol and left in the alcohol mixture at -20°C overnight. The precipitate was then removed by centrifugation, and washed twice with 75% strength ethanol, twice with absolute ethanol and twice with diethyl ether. After drying in an oven, a loose-packed dry RNA was obtained, which was stored in a dark glass vessel at room temperature.

#### Method II

This method is also suitable for extracting large quantities of yeast (kilogram quantities).

A given weight [sic] of yeast was homogenized in four times the amount of buffer (A) (see method I above) in the cold room. 40% v/v of phenol solution (B) and 5% w/v ice cubes made of deionized water were added to the homogenate and the mixture was stirred for 30 minutes. The supernatant was removed by suction and then phenolized two more times, as described under method I.

The aqueous supernatants were collected in a vessel which contained a DEAE-cellulose suspension (approx. 10% w/v, Whatman DE-22), corresponding to half the volume of the collected supernatants. The DEAE suspension was kept in suspension by stirring for 30 minutes. The DEAE was then allowed to sediment over one hour. The supernatant was removed by suction. In the meantime, the intermediate phase and phenol phase were stirred two more times with the aliquot amount of solution (C) (83% deionized water, 15% w/v ice cubes, 2% Mg-acetate concentrate [0.5M Mg-acetate in 0.25 [lacuna] mercaptoethanol] for 30 minutes and then allowed to separate for 70-80 minutes. The aqueous solutions were transferred into the vessel containing DEAE, and then again stirred and allowed to sediment. The supernatant was removed by suction and the DEAE was washed, as above, first twice with solution C, then again with solution (D) (2 volumes of Mg-acetate concentrate, 2 volumes of NaCl concentrate [3.75 M NaCl in water], 0.2 volumes of Tris-HCl concentrate [2.5 M Tris-HCl, pH 7.5 in water, 96 volumes of water]).

DEAE-cellulose was then packed into a column which was closed at the bottom. All further steps were carried out in the cold room at 4°C. The column was washed with 12 times the amount of the column contents of solution (D), flow rate 1.4 l/h, (only by gravity). The tRNA was then eluted with solution E [2 volumes of Mg-acetate concentrate, 0.2 volumes of Tris-HCl concentrate, 14 volumes of NaCl concentrate and 84 volumes of water, final NaCl concentration 0.525 M, with a flow of 3 l/h. The fractions which contained more than 35 A<sub>260 nm</sub> units/ml were combined and precipitated with 1.5 volumes of ethanol. The further procedure was according to method I.

Alternatively, the final precipitate can be taken up in water and can be lyophilized.

A variant of this method is the common phenolization of the starting material: crude tRNA is precipitated out of the upper phase with isopropanol. After centrifugation, the precipitate is extracted with the sodium acetate buffer and chromatographed on DEAE-cellulose. Elution is carried out with a sodium acetate/sodium chloride gradient, as it is known to biochemists experienced in the subject-matter. The suitable fractions, see above, are determined by means of quotient measurement and combined. The tRNA is precipitated with ethanol, the precipitate is taken up as above and is preferably lyophilized.

The following assays were employed for analyzing the purity of the total RNA and tRNA and for characterizing them:

Protein was determined according to Lowry, O.H. et al. (J. Biol. Chem. 193, 265 (1951)) and by  $A_{260}/A_{280} \cong 2$ , DNA according to Dische (Mikrochemie 8, 4 (1930), total RNA according to Mejbaum (Physiol. Chem. 258, 117 (1939)), quantitative determination of tRNA and of amino acid incorporation according to Sprinzl and Sternbach (Methods in Enzymology 59, 182 (1979)) toxicity according to M. Nöldner (personal communication), absence of pyrogen *in vitro* according to DAB 1997 (LAL assay) and *in vivo* according to Ph. Eur./DAB 1997.

#### Results of the analyses:

(Properties of total RNA and tRNA, averages from ten tests)

#### Absorption

$A_{260}/A_{280} \cong 1.94-2.0$

#### C,H,N analysis

C	32.67	32.42
H	5.22	5.20

N 2.29 2.00

with corresponding values of various total RNAs and tRNAs.

UV and IR spectra

- 5 The UV and IR spectra vary, they are almost the same but not identical, corresponding to biological substances.

Molecular weight

- 10 Total RNA and tRNA from yeast  $\cong$  22 000-27 000 dalton average, varying for different preparations;

	Protein	DNA (Total contents)
	2.3%	neg. Total RNA of <i>Saccharomyces cerevisiae</i>
15	1.9%	neg. tRNA of <i>Saccharomyces cerevisiae</i>
	0.9%	neg. Total RNA of bovine origin

- 20 Average, generally common quality. Improved purity led to no significantly improved therapeutic action, at a disproportionally higher cost.

Amino acid incorporation for tRNA, average of 10 analyses

	Lysine	69-85	pmol/A <sub>260</sub> unit
25	Phe	41-55	
	Ser	39-50	
	Val	77-90	

- 30 These averages vary in yeasts of different lots within the range stated.

Toxicity

Test for acute toxicity in mice:

- 35 Animals: NMRI mice, male, Janvier, France  
Administration: Intravenously into a tail vein  
Observation period: 24 hours  
Number of random samples: n = 10 at highest concentration

Assay substance: a. bovine total RNA  
b. tRNA from brewer's yeast  
(*Saccharomyces cerevisiae*)

Solvent: 0.9% NaCl in water p.i.

5 Result:

Up to a maximum dosage of 1g/kg/10 ml i.v., the animals used in the test showed no conspicuous features whatsoever within the observation period of 24 hours.

10 Absence of pyrogen

A. The pyrogen content of total RNA and tRNA, both as described previously, was determined using the in-vitro assay for endotoxins according to DAB 1997 (LAL TEST) and on rabbits according to Ph. Eur./DAB 1997.

15

1. Total RNA

Endotoxin standard EC 5

Amoebocyte lysate

- Sensitivity declared: 0.06 EU/ml

20 - Sensitivity found: 0.06 EU/ml

Test solution: 100 mg RNA dissolved in 20 ml of water-LAL (0.5%)

Result:

25 Endotoxin content of the test solution 0.5% 1:5 diluted with water-LAL: < 0.03 EU/ml.

2. tRNA

Endotoxin standard EC 5

30 Amoebocyte lysate

- Sensitivity declared: 0.06 EU/ml

- Sensitivity found: 0.06 EU/ml

Test solution: 100 mg RNA dissolved in 20 ml of water-LAL (0.5%)

35

Result:

Endotoxin content of the test solution 0.5% 1:10 diluted with water-LAL: < 0.03 EU/ml.

B. In vivo test for absence of pyrogen according to Ph. Eur./DAB 1997

1. Total RNA

Test solution 1% of assay substance in pyrogen-free water p.i.

Dose: 1.0 ml/animal

animals: 3 rabbits, corresponding to DAB 1997

Result:

Sum of temperature differences of 3 rabbits was 1.05°C, thus pyrogens are not detectable.

2. tRNA

Test solution 1% of assay substance in pyrogen-free water p.i.

Dose: 1.0 ml/animal

animals: 2 times 6 rabbits, corresponding to DAB 1997

Result:

- a. Sum of temperature differences of 6 rabbits: 5.40°C
- b. Sum of temperature differences of 6 rabbits: 4.10°C, pyrogens detectable.

**Example 2**

Detection of the efficacy of the substances of the present invention

70 Patients, 40 of these having herpes simplex I (H. labialis and 30 patients having herpes simplex II (H. genitalis), all having frequent recurrences, were treated with total RNA. The RNA came from extracts of bovine fetal tissue, with the exception of liver. The powder-like RNA was applied to the slightly wetted lesions, 5 to 10 mg, depending on the size of the lesion, and allowed to dry. All patients were observed for 1 year.

5 Patients were nonresponders with respect to

recurrences, 7 patients could not be analyzed, due to insufficient compliance. All other patients who always had several recurrences per year showed a significant decrease in recurrences. The evaluation was carried out  
5 by means of the nonparametric Mann-Whitney U test. The significance of the results was  $p < 0.001$ . (SPSS, Npar, Mann-Whitney U test).

10 In a double-blind study with an observation period of 1 year, two groups of in each case 100 patients having herpes simplex labialis and herpes simplex genitalis with more than 4 recurrences per year were treated with bovine total RNA as above or with tRNA from brewer's yeast. Evaluation was carried out after one year using  
15 the program SPSS, Npar TEST: Mann-Whitney and  $\chi^2$  test.

In comparison with the placebo patients, the reduction in recurrences was was [sic] highly significant: in both cases  $p < 0.001$ . The difference between the two  
20 RNAs was not large.

These results justify the use of said RNA in patients, in particular since no side effects or toxic symptoms whatsoever could be observed over several years.

25 When applying the described substances to facial herpes simplex in patients which also had a facial basalioma, it was found that said basalioma receded. Therefore the indication of the medicine of the invention also  
30 includes malignancies.



## Claims

1. A medicament, in particular for the treatment of  
Herpesviridae infections and/or of skin tumors,  
5 characterized in that  
it comprises xenogeneic oligo- and/or polyribo-  
nucleotides as active substance.
2. The medicament as claimed in claim 1,  
10 characterized in that  
it additionally comprises physiologically  
acceptable carriers, excipients, diluents and/or  
additives.
- 15 3. The medicament as claimed in claim 1 or 2,  
characterized in that  
the active substance comprises oligo- and/or  
polyribonucleotides from animal tissues, plants  
and/or unicellular organisms.
- 20 4. The medicament as claimed in claim 3,  
characterized in that  
the active substance comprises oligo- and/or  
polyribonucleotides from yeast cells.
- 25 5. The medicament as claimed in any of the preceding  
claims,  
characterized in that  
the active substance comprises xenogeneic tRNA.
- 30 6. The medicament as claimed in any of the preceding  
claims,  
characterized in that  
the active substance comprises xenogeneic oligo-  
35 and/or polyribonucleotides obtained by phenol  
extraction.
7. The medicament as claimed in any of the preceding

claims,  
characterized in that  
the xenogeneic oligo- and/or polyribonucleotides  
originate from organisms which are evolutionarily  
distant from the organism to be treated.

5

8. The medicament as claimed in any of the preceding  
claims,  
characterized in that  
the oligo- and/or polyribonucleotides are present  
in an anhydrous form.

10

9. The medicament as claimed in any of the preceding  
claims,  
characterized in that  
it is present in a form suitable for topical  
administration.

15

10. The use of xenogeneic oligo- and/or  
polyribonucleotides for the treatment of  
infections by Herpesviridae and/or skin tumors.

20

11. The use as claimed in claim 10 for the treatment  
of lesions of the skin and/or mucosa, caused by  
herpes simplex virus and/or varicella zoster  
virus.

25

12. The use as claimed in claim 10 for the treatment  
of basaliomas.

30

13. The use of xenogeneic oligo- and/or  
polyribonucleotides for producing a medicament for  
the treatment of infections by Herpesviridae  
and/or skin tumors.

35

14. A method for the treatment of infections by  
Herpesviridae and/or skin tumors,  
characterized in that  
an active amount of 0.1 mg and higher of

xenogeneic oligo- and/or polyribonucleotides per dose unit is administered to a patient or animal requiring a treatment of this kind.

Nov. 16, 2001

- 1 -

International Patent Application

PCT/EP00/08279

Seinfeld, Hugo, Prof.

5 11185P WO/HBwr

## New patent claims

- 10 1. The use of xenogeneic oligo- and/or polyribonucleotides for producing an anhydrous medicament for the topical treatment of infections by Herpesviridae and/or skin tumors, the medicament being applied once per recurrence.
- 15 2. The use as claimed in claim 1, characterized in that the medicament additionally comprises physiologically acceptable carriers, excipients, diluents and/or additives.
- 20 3. The use as claimed in claim 1 or 2, characterized in that the xenogeneic oligo- and/or polyribonucleotides originate from organisms which are evolutionarily
- 25 distant from the organism to be treated.
- 30 4. The use as claimed in any of the preceding claims for the treatment of lesions of the skin and/or mucosa, caused by herpes simplex virus and/or varicella zoster virus.
- 35 5. A method for the treatment of infections by Herpesviridae and/or skin tumors, characterized in that an active amount of 0.1 mg and higher of

AMENDED SHEET

xenogeneic oligo- and/or polyribonucleotides in an anhydrous preparation per dose unit is administered once per recurrence to a patient or animal requiring a treatment of this kind.

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES  
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum  
Internationales Büro



(43) Internationales Veröffentlichungsdatum  
8. März 2001 (08.03.2001)

PCT

(10) Internationale Veröffentlichungsnummer  
**WO 01/15704 A1**

(51) Internationale Patentklassifikation<sup>7</sup>: A61K 31/70,  
A61P 31/22, 35/04

(21) Internationales Aktenzeichen: PCT/EP00/08279

(22) Internationales Anmeldedatum:  
24. August 2000 (24.08.2000)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:  
199 40 748.7 27. August 1999 (27.08.1999) DE

(71) Anmelder und

(72) Erfinder: SEINFELD, Hugo [DE/DE]; Königinstrasse  
69, D-80539 München (DE).

(74) Anwälte: WEICKMANN, H. usw.; Kopernikusstrasse 9,  
81679 München (DE).

(81) Bestimmungsstaaten (national): AE, AG, AL, AM, AT,  
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU,

CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Bestimmungsstaaten (regional): ARIPO-Patent (GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), eura-  
sisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI,  
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI-Patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE,  
SN, TD, TG).

**Veröffentlicht:**

- Mit internationalem Recherchenbericht.
- Vor Ablauf der für Änderungen der Ansprüche geltenden  
Frist; Veröffentlichung wird wiederholt, falls Änderungen  
eintreffen.

Zur Erklärung der Zweibuchstaben-Codes, und der anderen  
Abkürzungen wird auf die Erklärungen ("Guidance Notes on  
Codes and Abbreviations") am Anfang jeder regulären Ausgabe  
der PCT-Gazette verwiesen.

WO 01/15704 A1

(54) Title: MEDICAMENTS THAT CONTAIN XENOGENIC OLIGO- OR/AND POLYRIBONUCLEOTIDES

(54) Bezeichnung: ARZNEIMITTEL ENTHALTEND XENOGENE OLIGO- ODER/UND POLYRIBONUKLEOTIDE

(57) Abstract: The invention relates to medicaments that contain xenogenic oligo- or/and polyribonucleotides as the effective component. The invention further relates to the use of said xenogenic oligo- or/and polyribonucleotides for treating herpesviridae infections and skin tumors.

(57) Zusammenfassung: Die Erfindung betrifft Arzneimittel, die als wirksamen Bestandteil xenogene Oligo- oder/und Polyribonukleotide enthalten. Weiterhin betrifft sie die Verwendung dieser xenogenen Oligo- oder/und Polyribonukleotide zur Behandlung von Infektionen durch Herpes viridae und Hauttumoren.

# DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "Medicaments containing xenogeneic oligo- and/", the specification of which or polynucleotides

( ) is attached hereto.

(X) was filed on August 24, 2000 as Application Serial No. PCT/EP00/08279

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

## Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

### Priority Claimed

<u>199 40 748.7</u>	<u>Germany</u>	<u>August 27, 1999</u>	Yes (X) No ( )
(Number)	(Country)	(Day/Month/Year Filed)	
<u>                    </u>	<u>                    </u>	<u>                    </u>	Yes ( ) No ( )
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

**U.S. Priority Applications**

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

\_\_\_\_\_  
(Applic. Serial No.)                      (Filing Date)                      (Status-patented/pending/abandoned)

\_\_\_\_\_  
(Applic. Serial No.)                      (Filing Date)                      (Status-patented/pending/abandoned)

**Power of Attorney**

I hereby appoint the following attorneys and patent agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Peter F. Felfe, Reg. No. 20,297; John E. Lynch, Reg. No. 20,940; Norman D. Hanson, Reg. No. 30,946; John A. Bauer, Reg. No. 32,554; Mary Anne Schofield, Reg. No. 36,669; James Zubok, Reg. No. 38,671; James R. Crawford, Reg. No. 39,155; Andrew Im, Reg. No. 40,657 and David Rubin, Reg. No. 40,314; my attorneys with full power of substitution and revocation.



Address all telephone calls to \_\_\_\_\_ at (212) 318-3000.

Address all correspondence to: FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue  
New York, New York 10103

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Hugo SEINFELD

February 4, 2002

Full Name/Sole or First Inventor

Signature

Date

Residence: Königinstraße 69  
80539 München, Germany

Post Office Address: same as above

Citizenship: German

(2)

Full Name/Second Inventor

Signature

Date

Residence: \_\_\_\_\_  
\_\_\_\_\_

Post Office Address: \_\_\_\_\_

Citizenship: \_\_\_\_\_